Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,404.00
Bid: 12,416.00
Ask: 12,418.00
Change: 44.00 (0.36%)
Spread: 2.00 (0.016%)
Open: 12,330.00
High: 12,450.00
Low: 12,316.00
Prev. Close: 12,360.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Australia backs Pfizer virus vaccine over AstraZeneca for under-50s

Thu, 08th Apr 2021 02:20

* Policy shift will hold up vaccination campaign, says PM

* People with first shot should still get their second

* Italy, UK have suggested AstraZeneca shot age limits
(Adds quote from chief health officer, prime minister and adds
detail)

By Colin Packham and Jonathan Barrett

CANBERRA/SYDNEY, April 8 (Reuters) - Australia said on
Thursday it now recommends people under 50 should get Pfizer's
COVID-19 vaccine in preference to AstraZeneca's
shot, a policy shift that it warned would hold up its
inoculation campaign.

The move, a day after European regulators reiterated they
had found possible links between AstraZeneca's shot and reports
of very rare cases of blood clots, is a huge hurdle for
Australia's programme, which had relied on that vaccine.

Australia's Chief Medical Officer, Paul Kelly, told
reporters the risk of clots was extremely low.

"It's only been found in the first dose of the AstraZeneca
vaccine, usually within 4 to 10 days after that vaccine. But it
is serious, and it can cause up to a 25% death rate when it
occurs," he said.

Australia would advise health providers to only give a first
dose of the AstraZeneca vaccine to adults younger than 50 when
the benefit clearly outweighs the risks, he added.

Italy and Britain on Wednesday joined other countries in
suggesting age limits for AstraZeneca's vaccine. But the
European regulators reaffirmed the importance of that shot in
protecting people against COVID-19.

Those who have already had a first AstraZeneca dose without
any serious adverse events "can safely be given their second
dose," Kelly said.

Prime Minister Scott Morrison said the updated advice will
delay Australia's inoculation timetable, but it was too soon to
say when Canberra would now vaccinate its adult population.

"There will be a recalibration of how the programme will
need to be adjusted," Morrison told reporters in Canberra.

Australia has ordered 20 million doses of the Pfizer vaccine
and Morrison said Canberra was in talks to increase the order.

Authorities will continue to give the AstraZeneca vaccine to
people over 70. Those over 50 who opt for the Pfizer vaccine
will have to wait, the government said.

Australia - which had planned to use the AstraZeneca vaccine
for the vast majority of its near 26 million population -
expected to give all adults at least one shot by October.

But its immunisation campaign was already heavily behind
schedule.

It had pledged to administer at least 4 million first doses
by the end of March, but could only deliver 670,000, with the
government blaming the delay on supply issues in Europe.

It had been looking to ramp up the immunisation effort,
underpinned by plans to make 50 million doses of AstraZeneca
vaccine in Australia, produced by CSL Ltd.

Australia began vaccinations much later than some other
nations because of its few infections, which stand at just under
29,400, with 909 deaths, since the pandemic began.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Interactive graphic tracking global spread of coronavirus:
https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

(Reporting by Colin Packham and Jonathan Barrett; Editing by
Michael Perry, Clarence Fernandez and Andrew Heavens)

More News
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.